FDA approves Moderna's first mRNA-based influenza vaccine

The FDA approved the first mRNA-based influenza vaccine, developed by Moderna, for adults ages 50 and older. The approval marks a milestone for mRNA technology first widely used during the COVID-19 pandemic, though multiple posts raise safety and efficacy concerns.

Detected & updated continuously · Source: Nebula

Story subjects

Food and Drug AdministrationModerna, Inc.mRNA influenza vaccine

Sources

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula